Skip Navigation


NDT Advance Access originally published online on January 18, 2007
Nephrology Dialysis Transplantation 2007 22(4):1027-1029; doi:10.1093/ndt/gfl762
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/4/1027    most recent
gfl762v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ulrich, C.
Right arrow Articles by Stockfleth, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ulrich, C.
Right arrow Articles by Stockfleth, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Azathioprine, UV light, and skin cancer in organ transplant patients—do we have an answer?*

Claas Ulrich and Eggert Stockfleth

Department of Dermatology, Skin Cancer Center Charité – Universitätsmedizin Berlin Schumannstrasse 20-21, 10117 Berlin, Germany

Correspondence and offprint requests to: Prof. Dr E. Stockfleth, Department of Dermatology, Skin Cancer Center Charité, Universitätsmedizin Berlin, Schumannstrasse 20-21, 10117 Berlin, Germany. Email: Eggert.stockfleth@charite.de

Keywords: Azathioprine; organ transplant patients; skin cancer; UV light

The first 10% of the full text of this article appears below.

The remarkable story of transplant medicine currently benefits more than 35 000 patients in the EU and US annually [1]. Patient and organ survival time has steadily increased over the years, and according to a recent analysis of 94 934 kidney transplant recipients, the half-life for kidney transplants has nearly doubled from 1988 to 1996 [2].

However, with increasing graft and patient survival, the focus of medical disciplines involved in the aftercare of transplant recipients is shifting towards managing the direct and indirect consequences of chronic immunosuppression [3,4]. The development of cutaneous infections and skin cancers is frequently observed in patients with impaired immunosurveillance, culminating in significant morbidity and even mortality in organ transplant recipients (OTR) [5].

A comprehensive study examining the US-Medicare billing claims of more than 35 765 kidney transplanted patients showed . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?